Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling
SEOUL, South Korea, December 2, 2025 — Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 studies at the Radiological Society of North America (RSNA) 2025 Annual Meeting. Spanning screening mammography, digital breast tomosynthesis (DBT), breast density science, and risk modeling, this year’s program represents one of the company’s most extensive evidence portfolios to date. Lunit will exhibit at South Hall, Booth #4100, and host expert-led sessions in the Lunit Education Room #1252 throughout the meeting.
Among the highlighted research, real-world results from Capio S:t Göran Hospital in Sweden evaluated more than 193,000 screening examinations before and after the introduction of Lunit INSIGHT MMG. When AI was paired with a single radiologist, the screening program achieved higher invasive cancer detection, greater positive predictive value, and fewer unnecessary recalls compared to human-only double reading—reinforcing findings from the ScreenTrustCAD interventional trial and demonstrating that AI-integrated single reading can maintain or improve accuracy while alleviating workforce pressure.
New evidence from Massachusetts General Hospital assessed AI performance on screening DBT using 1,000 retrospective examinations, showing that Lunit INSIGHT DBT correctly localized 84.4% of true-positive cancers, with particularly strong performance for mass-presenting and invasive ductal carcinoma cases. The study also detailed cancer subtypes less likely to be identified by AI, offering practical insight into the algorithm’s strengths and limitations as DBT adoption accelerates worldwide.
Further expanding the evidence base, two oral presentations from Elizabeth Wende Breast Care explored how volumetric breast density, as quantified by AI-powered algorithms, and family history influence risk stratification across leading models, as well as how density changes over time affect prediction consistency. In a cohort of 44,651 women, Tyrer-Cuzick classified substantially more women as high-risk than BOADICEA, driven by heavier weighting of density and family history inputs. A complementary longitudinal analysis of 335,000+ images demonstrated that incorporating volumetric breast density over time improved calibration and discrimination, while static or categorical density inputs consistently underestimated cancer incidence. Together, these findings strengthen the role of density-informed and longitudinal risk modeling in supporting risk-adapted screening strategies.
Lunit will also host a series of expert-led sessions in its Education Room #1252, offering deeper clinical and scientific perspectives on key themes presented at RSNA. Highlights include:
A cross-disciplinary discussion featuring Drs. Graham Colditz, Joy Jiang, and Hari Trivedi, exploring how image-based risk complements traditional models and what this means for more personalized, risk-adapted screening strategies.
Prof. Fiona Gilbert (University of Cambridge) will present new evidence on the ability of AI to identify interval breast cancers typically missed during routine screening, outlining how AI-supported detection could reduce missed cancers and improve population-level screening outcomes.
Drs. Liz Morris (UC Davis Health) and Elizabeth Burnside (University of Wisconsin–Madison) will compare two distinct approaches to implementing breast AI in academic environments. The session will examine evidence, ethics, and practical considerations for responsible adoption.
Dr. Manisha Bahl (Mass General) will share new clinical data on how Lunit INSIGHT DBT performs in digital breast tomosynthesis workflows, highlighting improvements in cancer detection, diagnostic consistency, and the potential to reduce interval cancer rates when integrated into routine practice.
“RSNA is where the field looks to understand whether AI is delivering measurable clinical value, and this year’s program reflects that momentum,” said Brandon Suh, CEO of Lunit. “Across mammography, DBT, and density-driven risk modeling, our studies highlight how rigorously validated AI can enhance screening performance, support radiologists, and strengthen the foundation for risk-adapted care. We remain committed to generating evidence that drives responsible and meaningful adoption in clinical practice.”
###
À propos de Lunit
Fondée en 2013, Lunit (KRX : 328130) est un leader mondial dont la mission est de vaincre le cancer grâce à l'intelligence artificielle. Nos solutions cliniquement validées couvrent l'imagerie médicale, la santé mammaire et l'analyse des biomarqueurs, permettant ainsi un dépistage plus précoce, des décisions thérapeutiques plus éclairées et des résultats plus précis tout au long du parcours de soins contre le cancer.
Lunit propose une gamme complète de solutions allant de la prédiction des risques et du dépistage précoce à l'oncologie de précision. Notre suite Lunit INSIGHT, homologuée par la FDA, ainsi que nos solutions dédiées à la santé mammaire, facilitent le dépistage du cancer dans des milliers d'établissements médicaux à travers le monde, tandis que la plateforme Lunit SCOPE est utilisée dans le cadre de partenariats de recherche avec des leaders mondiaux de l'industrie pharmaceutique et du secteur des laboratoires pour la recherche sur les biomarqueurs et le développement de diagnostics compagnons.
Reconnue par plus de 10 000 établissements dans plus de 65 pays, Lunit allie une expertise médicale approfondie à des ensembles de données en constante évolution afin d'avoir un impact tangible, tant pour les patients que pour les cliniciens et les chercheurs. Basée à Séoul et disposant de bureaux à travers le monde, Lunit contribue activement à la lutte mondiale contre le cancer. Pour en savoir plus, rendez-vous sur lunit.io/en.
Contact presse
Lunit
Responsable des relations publiques internationales
Jaewhan Lee
jaewhan.lee@lunit.io
Appendix - Lunit RSNA 2025 Full Study List
Oral Presentations (8)
- #1 T3-SSBR05, COMPARING FOUR COMMERCIAL AI ALGORITHMS FOR STANDALONE BREAST CANCER DETECTION ON DIGITAL BREAST TOMOSYNTHESIS IN A DUTCH POPULATION-BASED SCREENING COHORT—Sarah D. Verboom, MSc, Radboud university medical center
- #2 T3-SSBR05, MAMMOGRAPHY BREAST CANCER SCREENING TRIAGE USING DEEP LEARNING: RETROSPECTIVE COMPARISON OF 7 COMMERCIAL AI ALGORITHMS—Joshua Rothwell, University of Cambridge
- #3 W2-SPBR, EXPLORING HOW AI INFLUENCES HUMAN DECISION MAKING AND GAZE BEHAVIOUR DURING MAMMOGRAPHY INTERPRETATION—Yan Chen, PhD, Nottingham University
- #4 W3-SSER02, COMPARISON OF THE ACCURACY OF ARTIFICIAL INTELLIGENCE SOFTWARE FOR THE DETECTION OF PNEUMOTHORAX ON CHEST RADIOGRAPHS—Katrina Nash, MBChB, Oxford University Hospital
- #5 M7-SSBR04, EVOLUTION OF BREAST CANCER SCREENING: FROM HUMAN-ONLY DOUBLE READING VIA AI-INTEGRATED DOUBLE READING TO AI-INTEGRATED SINGLE READING—Karin Dembrower, MD, PhD, Karolinska Institute
- #6 S5-SSBR02, COMPARING HIGH RISK ESTIMATIONS USING VOLUMETRIC BREAST DENSITY WITH TYRER-CUZICK AND BOADICEA RISK MODELS—Stamatia V. Destounis, MD, Elizabeth Wende Breast Care
- #7 M7-SSBR03, IMPACT OF BREAST DENSITY CHANGE OVER TIME ON RISK MODEL CALIBRATION AND PREDICTION ACCURACY—Stamatia V. Destounis, MD, Elizabeth Wende Breast Care
- #8 M7-SSBR04, COMPARISON OF BREAST DENSITY AND AJCC BREAST CANCER PATHOLOGICAL PROGNOSTIC STAGE IN SCREEN DETECTED AND INTERVAL CANCERS IN A UK PROGRAMME—Fleur Kilburn-Toppin, MBBChir, MA, University of Cambridge
Poster Presentations (6)
- #1 R5B-SPBR, OPTIMIZING AI POSITIVE FINDINGS ON PRIOR NEGATIVE MAMMOGRAMS FOR CONTRALATERAL BREAST CANCER DETECTION AFTER BREAST CANCER SURGERY: DISTINGUISHING TRUE FROM FALSE POSITIVES—Eun Kyung Park, MD, PhD, Seoul National University
- #2 S3A-SPBR, WHAT AI SEES - AND WHAT IT DOESN’T: EVALUATING THE DETECTION OF BREAST CANCER SUBTYPES ON SCREENING DIGITAL BREAST TOMOSYNTHESIS—Manisha Bahl, MD, MPH, Massachusetts General Hospital
- #3 M5A-SPBR, A BIOPHYSICS-BASED COMPUTATIONAL APPROACH BOTH OUTPERFORMS AND SYNERGIZES WITH A COMMERCIAL MAMMOGRAPHIC DENSITY ASSESSMENT SOFTWARE FOR BREAST CANCER PREDICTION—Andre Khalil, PhD, MS, University of Maine
- #4 M5A-SPBR, ARTIFICIAL INTELLIGENCE-DERIVED MAMMOGRAPHY SCORES CAN PREDICT ONCOTYPE DX RISK SCORES IN ESTROGEN RECEPTOR POSITIVE BREAST CANCERS—Jung-Oh Lee, MD, MSc, Seoul National University
- #5 T5A-SPBR, AI-BASED MAMMOGRAPHY SCORES FOR PREDICTING PATHOLOGIC AXILLARY METASTASIS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS—Na Lae Eun, MD, PhD, Severance Hospital
- #6 T5A-SPBR, ARTIFICIAL INTELLIGENCE (AI)-BASED MAMMOGRAPHY SCORES FOR PREDICTING PATHOLOGIC COMPLETE RESPONSE IN BREAST CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY—Na Lae Eun, MD, PhD, Severance Hospital
